For help on how to get the results you want, see our search tips.
1987 results
Categories
Human Remove Human filter
Medicine
Summaries of opinion Remove Summaries of opinion filter
Paediatric investigation plans Remove Paediatric investigation plans filter
Periodic safety update report single assessments Remove Periodic safety update report single assessments filter
PIP decision type
PM: decision on the application for modification of an agreed PIP Remove PM: decision on the application for modification of an agreed PIP filter
W: decision granting a waiver in all age groups for all conditions or indications Remove W: decision granting a waiver in all age groups for all conditions or indications filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Delstrigo, doravirine, lamivudine, tenofovir disoproxil (fumarate) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001695-PIP01-14-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Granules
Decision date: 02/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Pifeltro, doravirine (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001676-PIP01-14-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Granules
Decision date: 02/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001501-PIP04-19-M02, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 30/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Tecovirimat (monohydrate) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001205-PIP02-19-M02, Route(s) of administration: Oral use, Gastric use, Pharmaceutical form(s): Powder for oral suspension, Capsule, hard
Decision date: 30/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant human A disintegrin and metalloprotease with thrombospind type-1 motifs 13 (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001160-PIP01-11-M03, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for infusion
Decision date: 02/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kisplyx, Lenvatinib (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-001119-PIP03-19-M03, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 30/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kyntheum, brodalumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-001089-PIP02-13-M03, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 02/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Constella, linaclotide (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-000927-PIP01-10-M07, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard
Decision date: 30/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib (ABT-494) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology; Immunology-Rheumatology-Transplantation
PIP number: EMEA-001741-PIP02-16-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Prolonged-release tablet, Age-appropriate oral pharmaceutical form
Decision date: 06/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine, dolutegravir (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-001750-PIP01-15-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 02/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-001776-PIP01-15-M01, Route(s) of administration: Intravenous use, Subcutaneous use, Pharmaceutical form(s): Concentrate for solution for infusion, Solution for injection, Age-appropriate dosage form for parenteral use
Decision date: 02/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Odevixibat (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: EMEA-002054-PIP03-20-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Capsule, hard, Age-appropriate oral liquid dosage form
Decision date: 06/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entospletinib (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-002058-PIP01-16-M01, Route(s) of administration: Oral use, Gastric use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral solid dosage form
Decision date: 30/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Xenleta, Lefamulin (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-002075-PIP01-16-M03, Route(s) of administration: Intravenous use, Oral use, Pharmaceutical form(s): Concentrate for solution for infusion, Age-appropriate oral solid dosage form, Coated tablet
Decision date: 30/12/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Sirturo, bedaquiline fumarate (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Infectious diseases
PIP number: EMEA-000912-PIP01-10-M06, Route(s) of administration: Oral use, Pharmaceutical form(s): Tablet, Granules
Decision date: 16/11/2022, Last updated: 13/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Methylphenidate (hydrochloride) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-003189-PIP01-22-M01, Route(s) of administration: Oral use, Pharmaceutical form(s): Chewable tablet, Oral suspension
Decision date: 24/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor on activated T cells (rocatinlimab) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: EMEA-002886-PIP01-20-M02, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 31/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Evoncabtagene pazurgedleucel (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-002881-PIP01-20-M01, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Dispersion for injection
Decision date: 31/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Neisseria meningitidis serogroup B fHbp subfamily A, Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein, Neisseria meningitidis serogroup B fHbp subfamily B, Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein, Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein, Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein (MenABCWY) (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-002814-PIP02-21-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Powder and suspension for suspension for injection
Decision date: 30/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Respiratory syncytial virus stabilised prefusion F subunit vaccine (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Vaccines
PIP number: EMEA-002795-PIP02-21-M01, Route(s) of administration: Intramuscular use, Pharmaceutical form(s): Powder and solvent for solution for injection
Decision date: 24/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Exagamglogene autotemcel (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-002730-PIP04-21-M01, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Dispersion for infusion
Decision date: 24/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Garadacimab (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-002726-PIP01-19-M03, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 30/01/2023, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Bis-choline tetrathiomolybdate (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism
PIP number: EMEA-002232-PIP02-19-M02, Route(s) of administration: Oral use, Pharmaceutical form(s): Age-appropriate oral solid dosage form, Coated tablet
Decision date: 13/05/2022, Last updated: 09/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): daprodustat (updated)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Haematology-Hemostaseology; Uro-nephrology
PIP number: EMEA-001452-PIP01-13-M04, Route(s) of administration: Oral use, Pharmaceutical form(s): Dispersible tablet, Tablet
Decision date: 08/07/2022, Last updated: 07/11/2023, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Mayzent, Siponimod (hemifumarate)
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-000716-PIP01-09-M05, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 30/12/2022, Last updated: 25/10/2023, Compliance check: X